While RGS6 deficiency causes Parkinson's-like pathology, whether enhancing RGS6 function or targeting the D2R-Gi/o pathway can reverse or prevent established neurodegeneration remains untested. This is crucial for therapeutic development.
Gap type: open_question
Source paper: Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice. (2019, JCI Insight, PMID:31120439)
Restore RGS6 in substantia nigra pars compacta dopaminergic neurons after established alpha-synuclein pathology to test whether RGS6 loss is not only necessary but therapeutically reversible. The decisive experiment is delayed intervention in PFF or AAV-SNCA models with unbiased stereology, terminal preservation, dopamine physiology, and catalytically dead RGS6 controls.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["RGS6/Galphao Interaction GTPase-Activating Protein Recruitment"]
B["GPCR Signaling Suppression Gi/o-Mediated cAMP Reduction"]
C["DRD2 and ADORA2A Desensitization Dopaminergic Tone Modulation"]
D["Neuronal Survival Anti-apoptotic Program Maintenance"]
E["Dopaminergic Neuroprotection Substantia Nigra Viability"]
F["RGS6 Loss GPCR Hyperactivation and Nigral Degeneration"]
A --> B
B --> C
C --> D
D --> E
F -.->|"triggers"| E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#1b5e20,stroke:#81c784,color:#81c784
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Median TPM across 13 brain regions for RGS6 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
10 citations10 with PMIDValidation: 0%7 supporting / 3 opposing
✓For(7)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
RGS6 deficiency causes age-dependent nigral dopaminergic degeneration, alpha-synuclein accumulation, hyperactive D2 autoreceptor signaling, and reduced cAMP signaling, making RGS6 restoration the most direct therapeutic test of the causal axis.
Earlier mouse work independently linked loss of Rgs6 to Parkinsonian dopaminergic pathology, supporting necess…▼
Earlier mouse work independently linked loss of Rgs6 to Parkinsonian dopaminergic pathology, supporting necessity of endogenous RGS6 for nigrostriatal integrity.
Regulator of G protein signaling 6 mediates exercise-induced recovery of hippocampal neurogenesis, learning, a…▼
Regulator of G protein signaling 6 mediates exercise-induced recovery of hippocampal neurogenesis, learning, and memory in a mouse model of Alzheimer's disease.
RGS6 suppresses TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancers via a novel mec…▼
RGS6 suppresses TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancers via a novel mechanism dependent on its interaction with SMAD4.
RGS6 has been reported to promote mitochondrial and caspase-linked apoptosis in other systems, raising a nontr…▼
RGS6 has been reported to promote mitochondrial and caspase-linked apoptosis in other systems, raising a nontrivial safety liability for overexpression.
Additional studies also support pro-apoptotic RGS6 signaling, reinforcing concern that overexpression could wo…▼
Additional studies also support pro-apoptotic RGS6 signaling, reinforcing concern that overexpression could worsen neuronal loss rather than rescue it.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-25 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Therapeutic Hypotheses: RGS6 Upregulation & D2 Autoreceptor Modulation in Established Parkinson's Models
Hypothesis 1: AAV-Mediated RGS6 Overexpression in Substantia Nigra Rescues Established Dopaminergic Degeneration
Mechanism: Restoring RGS6 GTPase-activating function normalizes D2 autoreceptor signaling, reduces excessive Gi/o-mediated suppression of neuronal activity, and restores dopamine homeostasis. RGS6 also modulates Gβγ signaling to mitochondria, reducing ROS production and preventing cytochrome c release.
Target Gene/Protein/Pathway: RGS6 (Regulator of G Protein
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Several of these hypotheses over-interpret a loss-of-function phenotype as if it implied therapeutic gain-of-function, and several supporting citations are mismatched to the claims. After checking the primary literature, the basic anchor is solid: `Rgs6` loss produces age-dependent SNc degeneration, hyperactive D2 autoreceptor signaling, reduced cAMP signaling, motor deficits, and α-syn accumulation in mice ([JCI Insight 2019, PMID:31120439](https://pubmed.ncbi.nlm.nih.gov/31120439/); related earlier phenotype paper: [PLOS Genet 2014](https://journals.plos.org/plosgenetics/article?id=10.1371/j
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Feasibility Assessment: RGS6 and D2 Autoreceptor Modulation in Established PD Models
Executive Summary
The SKEPTIC's analysis effectively deflates most of these hypotheses, leaving two core testable approaches that warrant serious evaluation. The field's fundamental challenge is moving from a loss-of-function phenotype (Rgs6 deletion causes PD-like pathology) to a gain-of-function therapeutic claim (RGS6 overexpression prevents or reverses neurodegeneration) — a transition that requires substantially more evidence than the current literature provides. Below I assess the surviving ideas
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "AAV-mediated RGS6 re-expression in SNpc after pathology onset", "description": "Restore RGS6 in substantia nigra pars compacta dopaminergic neurons after established alpha-synuclein pathology to test whether RGS6 loss is not only necessary but therapeutically reversible. The decisive experiment is delayed intervention in PFF or AAV-SNCA models with unbiased stereology, terminal preservation, dopamine physiology, and catalytically dead RGS6 controls.", "target_gene": "RGS6", "dimension_scores": { "evidence_strength": 0.4
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF adult C57BL/6J mice receive bilateral AAV9-RGS6 injections into SNpc 60 days after AAV-SNCA overexpression (when alpha-synuclein pathology is established), THEN treated mice will exhibit significantly preserved rotarod latency (≥40% improvement vs. AAV-SNCA + AAV-GFP controls) and reduced parkinsonian motor deficits measured at 90 days post-RGS6 injection.
pendingconf: 0.65
Expected outcome: Motor function improvement (rotarod latency ≥25 s vs. ≤18 s in controls; akinesia latency ≥120 s vs. ≤80 s in controls), with behavioral rescue maintained at 120 days.
Falsified by: No significant difference in motor behavioral scores between AAV-RGS6 and AAV-GFP control groups (p > 0.05, two-way ANOVA with Bonferroni correction); or accelerated motor decline suggesting toxicity.
Method: AAV-SNCA Parkinson's model in C57BL/6J mice; stereotaxic AAV9-hSyn-RGS6-IRES-eGFP or AAV9-hSyn- GFP (1×10^9 vg) injection at 60 days post-SNCA; longitudinal rotarod, cylinder, and grid test from day 90-120; n≥12 per group; blinded observer scoring.
IF adult C57BL/6J mice receive bilateral AAV9-RGS6 injection into SNpc 45 days after PFF α-synuclein seeding (when phosphorylated α-synuclein aggregates are established), THEN stereological counting will reveal significantly higher SNpc TH+ neuron survival (≥60% vs. ≤35% in PFF + AAV-GFP) and striatal dopamine content (≥70% vs. ≤50% of sham) measured at 90 days post-RGS6 injection.
pendingconf: 0.55
Expected outcome: TH+ neuron count in SNpc ≥5,000 cells and striatal DA ≥0.8 μg/mg tissue, vs. ≤3,500 TH+ cells and ≤0.5 μg/mg in PFF + AAV-GFP controls.
Falsified by: RGS6 re-expression fails to preserve TH+ neurons (≤40% survival, p > 0.05 vs. PFF controls) or striatal dopamine content (≤55% of sham); or stereological counts show no difference between catalytically dead RGS6 and wild-type RGS9.
Method: PFF seeding model in C57BL/6J mice; intrastriatal 3 μg PFF injection at day 0; AAV9-DIO-RGS6 or AAV9-DIO-RGS6-G184R (catalytically dead) injected at day 45; sacrifice at day 90 for unbiased stereology (optical fractionator) and HPLC-EC dopamine measurement; n≥10 per group; experimenter-blinded analysis.
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
RGS6 — Search for structure
Click to search RCSB PDB